Thermo fisher scientific launches international corevitas clinical registry in adolescent atopic dermatitis, a chronic skin condition

Waltham, mass.--(business wire)--thermo fisher scientific inc., the world leader in serving science, today announced the launch of the international corevitas adolescent atopic dermatitis (ad) registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients. the registry recently enrolled its first european union patient, expanding its geographic footprint of enrollment beyond north america, where the first patient was enrolled in december 2023.
TMO Ratings Summary
TMO Quant Ranking